TOXICITY PROFILE RELATED TOIMMUNE CHECK POINT INHIBITORS:A COMPREHENSIVE REVIEW

Abstract

Immunotherapies are changing the scope of advanced solid tumour treatment. These molecules that increase the endogenous immune response against molecules that increase the endogenous immune response against tumours. They have revolutionized the field of oncology. Immune checkpoint inhibitors are monoclonal antibodies that are used to treat over one in three cancer patients, checkpoint inhibitors, such as CTLA-4 or PD1/PD-L1 monoclonal antibodies, and CSF-1R antibodies. Cancer immunotherapies have unique toxicity profile different from other cancer therapies, which presents difficult for physician in ruling out and addressing adverse effects produced by inflammation brought immune response activation. Any organ or system in the body may have adverse effects; however, GI, dermatologic, hepatic, endocrine, and pulmonary toxicities are the most frequent. Any changes should raise an alert that they are related to the medication. Immunerelated adverse effects (irAEs) vary with incidence and onset depending on the type and dosage of Immune check point inhibitors used. Checkpoint inhibitors therapy is frequently continued even in the event of minor irAEs. However, fatal results have been recorded in instances involving moderate to severe irAEs, and these toxicities require early detection along with suitable care. They can additionally lead to life-threatening decreases in organ function and health related quality of life (HRQL).